7 results about "He Antibody" patented technology

This invention provides a recombinant Staphylococcus aureus enterotoxin B nanoparticle protein vaccine, mSEB-mi3, its preparation method, and its applications. This invention utilizes a SpyTag / SpyCather protein linker system to connect the recombinant protein to the nanoparticle protein, allowing mSEB to be displayed on the surface of self-contained nanoparticles, thus obtaining the recombinant Staphylococcus aureus enterotoxin B nanoparticle protein mSEB-mi3. Both mSEB-SpyTag and SpyCather-mi3 proteins in this invention are induced to be expressed in soluble form in Escherichia coli. The mSEB-SpyTag and SpyCather-mi3 of this invention can be covalently bound via isopeptide bonds to form the mSEB-mi3 nanoparticle protein vaccine. The binding conditions are simple, and when combined with the adjuvant MF59, it can induce rapid antibody production in mice, generating a high-level immune response and exerting a protective effect. Furthermore, its antibody response rate and protective efficiency are superior to those of the monomeric protein mSEB.

We provide camptothecin-based pharmaceuticals and their antibody conjugates. [Solution] A compound of the following formula I and its antibody complex are provided. JPEG2026086826000042.jpg62170 (In formula I, R1 and R2 are independently a C1-C3 alkyl group, -H, -CF3, aryl group, heteroaryl group, etc.)

This invention provides a series of antibodies or antigen-binding fragments thereof that have high specific binding ability to tumor cells expressing the ITGA2 protein. The antibodies or antigen-binding fragments of this invention can achieve excellent killing effects against tumor cells after being conjugated with a drug to form an antibody-drug conjugate.

The application discloses an inhibitory antibody or antigen-binding fragment thereof against human OX40, a preparation method and application, and belongs to the technical field of biological immunity. The human-mouse chimeric antibody Y07-L2 and the humanized antibody Y07-C2 prepared by the application have similar EC50 in combination with human OX40, and are similar to the targeted antibody drug KHK-4083 in inhibiting OX40. The heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is shown as SEQ ID NO. 14, and the light chain variable region is shown as SEQ ID NO. 15; the heavy chain variable region of the humanized antibody Y07-C2 is shown as SEQ ID NO. 20, and the light chain variable region of the humanized antibody Y07-C2 is shown as SEQ ID NO. 21; the CDR region of the humanized antibody Y07-C2 is subjected to mutation, and the mutant antibody Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

This invention discloses an anti-ROR1 antibody or its antigen-binding fragment, relating to the fields of biotechnology and medical technology. Ten antibodies with high affinity for the ROR1 protein were screened and can specifically bind to it. This allows for the development of ROR1 detection kits, tumor diagnostic and prognostic kits, as well as antibody-containing pharmaceutical compositions, antibody-drug conjugates, and other antibody-based therapeutic methods. Experimental verification shows that the antibodies provided by this invention have a high killing rate against tumor cells. All of the above antibodies exhibit antibody concentration-dependent cytotoxicity (ADCC), with higher antibody concentrations resulting in better anti-tumor activity. Therefore, the antibodies or their antigen-binding fragments provided by this invention show promising potential for the preparation of tumor therapeutic drugs.

The application discloses a novel coronavirus neutralizing antibody, a detection kit and application thereof, an amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No. 1, and an amino acid sequence of a light chain variable region is shown as SEQ ID No. 2. The application screens the affinity-matured antibody through bioinformatics analysis of a single B cell, combines single-cell RNA sequencing, VDJ rearrangement analysis and somatic hypermutation research, optimizes the antibody screening process, avoids blindness of a traditional method, and improves the accuracy and effectiveness of antibody screening. The neutralizing antibody GR12 provided by the application can specifically combine with a RBD domain of SARS-CoV-2 and a S-Trimer domain of an Omicron mutant strain through the heavy chain and light chain variable regions, realizes broad-spectrum neutralization of SARS-CoV-2 and mutant strains thereof, and the antibody GR12 is significantly superior to other antibodies in the binding activity of S-Trimer and RBD under 2-fold and 300-fold dilution conditions, indicating that the antibody has high affinity and dilution stability, and is suitable for clinical large-dose administration requirements.

The invention provides a blocking type GIPR antibody, an antigen binding fragment thereof, an antibody conjugate and application of the antibody conjugate in preparation of drugs. The GIPR antibody and the antigen binding fragment thereof have relatively high affinity to GIPR protein, and are combined with the GIPR protein expressed on the surface of a cell to block the activity of the GIP activated cell; the GIPR antibody has relatively good cell internalization activity, pharmacokinetic studies show that the GIPR antibody and the antigen binding fragment thereof show relatively good stability in a mouse body, and AUC0-t can be up to 15033.01 hou * [mu] g / mL at most. An antibody conjugate prepared from the GIPR antibody shows the activity of stably and lastingly reducing the weight of an experimental animal model, and has a wide application prospect.